Critical Contrast: Corium International (CORI) versus Its Rivals

Corium International (NASDAQ: CORI) is one of 105 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Corium International to related businesses based on the strength of its profitability, valuation, institutional ownership, earnings, dividends, risk and analyst recommendations.

Analyst Recommendations

This is a summary of current recommendations and price targets for Corium International and its peers, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Corium International 0 0 6 0 3.00
Corium International Competitors 898 3891 6890 183 2.54

Corium International presently has a consensus price target of $13.00, indicating a potential upside of 28.33%. As a group, “Pharmaceuticals” companies have a potential upside of 18.80%. Given Corium International’s stronger consensus rating and higher possible upside, analysts plainly believe Corium International is more favorable than its peers.

Profitability

This table compares Corium International and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Corium International -149.99% -482.64% -62.37%
Corium International Competitors -2,432.13% -66.91% -7.47%

Valuation & Earnings

This table compares Corium International and its peers gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Corium International $31.86 million -$47.79 million -6.07
Corium International Competitors $8.31 billion $1.11 billion 145.50

Corium International’s peers have higher revenue and earnings than Corium International. Corium International is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

89.1% of Corium International shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 45.7% of Corium International shares are held by company insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk & Volatility

Corium International has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Corium International’s peers have a beta of 35.04, meaning that their average stock price is 3,404% more volatile than the S&P 500.

Summary

Corium International peers beat Corium International on 7 of the 13 factors compared.

Corium International Company Profile

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. The Company has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. Its late-stage pipeline includes a contraceptive patch, which has completed Phase III trials, and additional transdermal products that are being developed with other partners. Its products include Clonidine TDS, Fentanyl TDS and Crest Whitestrips. Its pipeline products include Twirla, Corplex Donepezil and Corplex Memantine, Donepezil, Corplex Ropinerole, MicroCor hPTH(1-34) and Motion Sickness Patch.

What are top analysts saying about Corium International? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Corium International and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit